Skip to main content

Table 4 Medication use during the course of the disease (percentage)

From: Juvenile Psoriatic Arthritis (JPsA): juvenile arthritis with psoriasis?

  ERA N=16 Persistent oligoarticular course N=44 Extended oligoarticular course N=21 RF-polyarticular N=34 Polyarticular course N=55 Total cohort N=115 P value
Methotrexate 4 (25.0) 8 (18.2) 10(47.6) 13(38.2) 23 (41.8) 35 (22.6) 0.03
Anti-TNF agent 2 (12.5) 1 (2.3) 6(28.5) 2(5.9) 7* (12.7) 10 (8.7) 0.16
Etanercept 1 (6.2) 1 (2.3) 5(23.8) 2(5.9) 7 (12.7) 9 (7.8) 0.15
Infliximab 1 (6.2) 0 (0) 1(4.7) 0(0) 1 (1.8) 2 (1.7) 0.26
Any DMARD 4 (25.0) 10 (22.7) 11(52.4) 14(41.2) 25 (45.4) 39 (33.9) 0.04
Prednisone 2 (12.5) 1 (2.3) 4(19) 3(8.8) 7 (12.7) 10 (8.7) 0.15
  1. * one patient was treated with both etanercept and infliximab.
  2. DMARD: Disease-Modifying Anti-Rheumatic Drug.